Head to head evaluation of second generation ALK inhibitors brigatinib and alectinib as first-line treatment for ALK+ NSCLC using an in silico systems biology-based approach

Around 3–7% of patients with non-small cell lung cancer (NSCLC), which represent 85% of diagnosed lung cancers, have a rearrangement in the ALK gene that produces an abnormal activity of the ALK protein cell signaling pathway. The developed ALK tyrosine kinase inhibitors (TKIs), such as crizotinib,...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Oncotarget
Egile Nagusiak: Carcereny, Enric, Fernández-Nistal, Alonso, López, Araceli, Montoto, Carmen, Naves, Andrea, Segú-Vergés, Cristina, Coma, Mireia, Jorba, Guillem, Oliva, Baldomero, Mas, Jose Manuel
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Impact Journals LLC 2021
Gaiak:
Research Paper
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7899557/
https://ncbi.nlm.nih.gov/pubmed/33659043
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.27875
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak